Wet AMD

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss risk factors for wet AMD. MD Newsline: Is there a genetic predisposition for wet AMD? Dr. Murtaza Adam: “Really, we don’t fully understand the genetic causes of age-related macular degeneration (AMD). We have implicated at least 70 genes in the development...

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss how to provide culturally sensitive care and overcome language barriers. MD Newsline: How have you been able to implement culturally sensitive care in your practice? Dr. Murtaza Adam: “Cultural sensitivity was a large component of my medical education. It wasn’t taught...

Razumab is the world’s first biosimilar ranibizumab. It has been approved for treating various types of macular disorders, including wet age-related macular degeneration (AMD). This prospective, multi-center, post-marketing study focuses on the safety and efficacy of biosimilar ranibizumab for patients with wet AMD. The 24-week study enrolled 126 patients with wet AMD. They were all...

The costs of treating wet age-related macular degeneration (AMD) are often very high, both at the individual and societal levels. This study focused on conducting a cost-benefit analysis of wet AMD treatment to understand the economic impact of these treatments. The study specifically compares three types of treatments: intravitreal bevacizumab, ranibizumab, and aflibercept. The study...

Several factors can increase the risk of developing age-related macular degeneration (AMD). This study focused on analyzing the association among IL-8 gene polymorphisms, IL-8 levels, and the risk of developing AMD. The study was conducted as a meta-analysis that relied on IL-8 -251A/T (rs4073) and +781C/T (rs2227306) polymorphisms and IL-8 levels in patients with AMD and...

This study focused on rates of hematologic inflammation in patients with age-related macular degeneration (AMD). Patients with wet AMD and dry AMD were included. The goal of the study was to find correlation patterns between hematologic inflammation and AMD, which could be useful for diagnostic and therapeutic purposes. This study analyzed data from 60 patients...

The World Health Organization (WHO) collects, studies, and develops eye care information for people worldwide. At the 70th World Health Assembly, it was suggested, with the support of experts, that WHO examine the current state of eye care and draw attention to effective strategies to increase patient access to eye care services. Although WHO reports...

The risk of visual impairment increases, and to some degree, is expected as we age. Visual impairment in the elderly is a prevalent issue across all racial and ethnic groups. The most common causes of visual impairment in the elderly are cataracts, glaucoma, and age-related macular degeneration (AMD). Cataracts can be corrected with surgery in...

Clinical trials are performed to develop new and better treatment methods. They are also a means for patients to receive expensive treatment. This fact is especially relevant for elderly patients suffering from neovascular age-related macular degeneration (AMD). Previous studies, such as the Vascular Endothelial Growth Factor Trap-Eye: Investigation of Efficacy and Safety in Wet AMD...